It is our mission to be a world leader in liquid biopsy and artificial intelligence for early detection of cancers and other diseases to improve survival and quality of life. Dxcover are an award-winning team, dedicated to developing liquid biopsies for early detection of cancer and other diseases. A University of Strathclyde spinout in 2019 under the name ClinSpec Diagnostics, and rebranded as Dxcover Limited in 2021. To date, Dxcover have secured £5.1m of funding, and have successfully completed two ground-breaking clinical studies on detection of brain cancer and are currently developing our platform for the detection of commonly occurring cancers.
PhysioMedics is a healthcare technology company which provides online software solutions to reduce costs and improve efficiencies in managing musculoskeletal disorders.
Cytomos Limited, based in Edinburgh, United Kingdom, specializes in developing advanced technologies for cell sorting and analysis in laboratory research and clinical diagnostics. Established in 2011, the company focuses on its patented Dielectric Spectroscopy (CDS™) technology, which allows for unbiased, label-free analysis of individual cells with single-cell resolution. This technology is particularly valuable in the biopharma and cell therapy sectors, as it enables automated and quantitative assessment of samples, aiding in phenotypic drug discovery and stem cell therapy. By leveraging proprietary machine learning algorithms, Cytomos provides deep insights into bioprocesses, enhancing the efficiency of cell-based diagnostics and enabling researchers to make informed decisions regarding dosage and treatment protocols.
BioCaptiva
Seed Round in 2022
BioCaptiva develops liquid biopsy technology devices to diagnose and monitoring to detect cancers.
Biotangents Ltd., founded in 2015 and based in Glasgow, United Kingdom, specializes in designing and building biological pathways for the production of valuable natural materials. The company utilizes its proprietary Leapfrog Assembly platform to create complex genetic constructs from various DNA components. Among its innovations is the development of terpenoid biosynthesis strains and the Short Sequence Randomisation technology for DNA randomisation. Biotangents has also conceptualized Moduleic Sensing, a modular cell-free nucleic acid detection technology, which led to the creation of a diagnostic test for identifying infectious diseases in livestock. This veterinary diagnostic device employs isothermal amplification technology, enabling precise detection without significant technical demands and allowing for quick adaptation to new targets. The solutions provided by Biotangents aim to mitigate the impact of infectious diseases in livestock, thereby enhancing the efficiency of animal protein production.
WellFish Diagnostics is on a mission to enhance the sustainability of the aquaculture industry by increasing productivity resulting from improved fish health and welfare. The company was founded in 2021 by Brian Quinn and is headquartered in Bridge of Weir, United Kingdom. .
Talking Medicines Limited is a data technology company based in Glasgow and London that specializes in capturing, curating, and structuring patient insights related to launched medicines. Utilizing advanced artificial intelligence, machine learning, and natural language processing, the company analyzes real-world conversations and behaviors of patients to map their experiences with medications. Its flagship application, Medsmart, collects data on medication usage, providing pharmaceutical companies with real-time intelligence about patient sentiment and behavior. The company offers various solutions, including a real-world persona data service, digital focus groups, and custom data solutions tailored to specific needs within the pharmaceutical sector. Founded in 2013 and rebranded in 2015, Talking Medicines aims to enhance regulatory compliance and enable marketing strategies through insights that measure patient confidence and identify growth opportunities for pharmaceutical brands.
Cytochroma manufacture genetically diverse stem cell-derived models to predict the safety and effect of drugs in a global population. Cytochroma’s automated cell manufacture, physiologically relevant models and rapid screening platform makes preclinical testing faster, safer and smarter.
Dyneval specializes in portable technology for cattle semen analysis, focusing on the precise measurement of semen quality. Its innovative technology assesses semen motility under quasi-in-vivo conditions, providing valuable insights into spermatozoa behavior. By utilizing dynescan data, Dyneval aids in informing breeding plans and confirming semen quality throughout the supply chain. This approach not only enhances livestock production but also contributes to improved food security and reduced methane emissions, allowing farmers to address issues related to poor conception rates effectively.
Altair Medical is developing real-time monitoring solutions to allow patients with respiratory conditions and their doctors to track their respiratory rates and performance out of hospital, at home and at work. Combining proprietary sensor technology and an innovative AI driven digital therapeutic software platform, Altair’s technology enables doctors to rationalise medication use, identify early signs of deterioration, reduce or shorten hospital admissions and reduce face to face appointments.
BioCaptiva
Seed Round in 2021
BioCaptiva develops liquid biopsy technology devices to diagnose and monitoring to detect cancers.
RAB Microfluidics specializes in developing innovative lab-on-a-chip technology aimed at transforming oil analysis processes. By utilizing patented microfluidic technology, the company offers real-time diagnostics for lubricated machinery, enabling early detection of potential failures and preventing costly equipment breakdowns. This dynamic approach provides clients with laboratory-quality data and actionable insights for effective asset condition management, significantly reducing costs compared to traditional methods. Founded on a decade of research from the University of Aberdeen, RAB Microfluidics is recognized as a pioneer in microfluidic technology for oil applications in Europe. With a dedicated advisory team boasting over 60 years of expertise, the company is committed to addressing the needs of diverse industries, including oil and gas, aerospace, and power generation, by making oil testing mobile, rapid, and routine.
Bio-Images Drug Delivery Ltd, located in Glasgow, United Kingdom, specializes in drug formulation and delivery systems. The company offers comprehensive services that include troubleshooting, formulation development, and both in vitro and in vivo testing. A key feature of their offerings is the patented OralogiK technology, which allows for precise control of drug release. This technology has been validated in clinical studies and enables the oral administration of single, multi-dose, or combination drugs at specific intervals ranging from one to twelve hours after ingestion. The benefits of this system include targeted night-time dosing, multi-phased drug delivery, and the ability to direct drugs to specific areas within the digestive system. Additionally, Bio-Images Drug Delivery employs gamma scintigraphy to assess the in vivo behavior of formulations, providing crucial data on disintegration times, gastric emptying, and gastrointestinal transit. The company's clinical division supports the entire clinical trial process, from protocol development to regulatory submissions and the production of compliant study reports.
Aurum Biosciences Ltd develops pharmaceuticals. The company’s products and technology include Perfluorocarbon which carry oxygen to organs and tissues; Magnetic Resonance Imaging which is a medical imaging technique that does not use ionising radiation and Proprietary image analysis software which provides accurate analyses of images of the stroke patient’s brain. Aurum Biosciences Ltd was founded in 2010 and is headquartered in Glasgow, United Kingdom.
ClinSpec Dx™ are pioneering a new spectroscopic method for blood serum analysis, allowing same-day detection and grading of a range of diseases, with first applications to brain cancer.
Manus Neurodynamica Ltd manufactures medical diagnostic technologies for neuromotor impairments, including the non-invasive diagnosis and monitoring of Parkinson’s disease. Its technologies are used in academic research, pharmaceutical research, and non-medical applications. The company was founded in 2008 and is based in North Shields, United Kingdom.
Current Health Limited, founded in 2014 and based in Edinburgh, United Kingdom, specializes in developing wearable healthcare devices that monitor patients' vital signs. These devices are designed to measure key health metrics such as oxygen saturation, respiration rate, pulse rate, temperature, motion, activity, and posture, allowing for the early identification of unwell patients and timely medical intervention. The company also offers a patient monitoring platform that facilitates home-based care by enabling patients to share daily activities, report symptoms, and respond to structured questionnaires for their healthcare providers. By focusing on remote patient management, Current Health aims to reduce healthcare risks and costs while enhancing patient engagement and monitoring. Formerly known as Snap40 Limited, the company rebranded in December 2018 to better reflect its mission.
Current Health Limited, founded in 2014 and based in Edinburgh, United Kingdom, specializes in developing wearable healthcare devices that monitor patients' vital signs. These devices are designed to measure key health metrics such as oxygen saturation, respiration rate, pulse rate, temperature, motion, activity, and posture, allowing for the early identification of unwell patients and timely medical intervention. The company also offers a patient monitoring platform that facilitates home-based care by enabling patients to share daily activities, report symptoms, and respond to structured questionnaires for their healthcare providers. By focusing on remote patient management, Current Health aims to reduce healthcare risks and costs while enhancing patient engagement and monitoring. Formerly known as Snap40 Limited, the company rebranded in December 2018 to better reflect its mission.
Adaptix Limited designs and manufactures 3D radiology imaging equipment for X-ray imaging applications. It offers a technology for producing a miniaturized flat panel X-ray source that can be integrated into a manufacturers existing product line. The company’s solutions are used in bedside chest imaging, extremity imaging, dental imaging, and breast imaging. Adaptix Limited was formerly known as Radius Diagnostics Ltd and changed its name to Adaptix Limited in February 2015. The company was founded in 2009 and is based in Oxford, United Kingdom.
Calcivis Limited is a dental biologic and device manufacturing company based in Edinburgh, United Kingdom, focused on addressing tooth decay and enhancing preventive dentistry. Established in 2012, the company has developed a unique imaging system that provides live visualization of active tooth demineralization. This system incorporates CALCIVIS photoprotein, which emits light in response to free calcium ions released from demineralizing tooth surfaces. The imaging device captures this reaction, allowing dental professionals to assess and diagnose caries and other demineralization conditions effectively. By enabling early detection of active decay, the technology supports a preventive approach to dentistry, aiming to treat patients before cavities necessitate more invasive procedures. Calcivis was co-invented with contributions from the University of Dundee and LUX Innovate, and it operates a virtual development model in collaboration with various Scottish contract research and manufacturing organizations.
Talking Medicines Limited is a data technology company based in Glasgow and London that specializes in capturing, curating, and structuring patient insights related to launched medicines. Utilizing advanced artificial intelligence, machine learning, and natural language processing, the company analyzes real-world conversations and behaviors of patients to map their experiences with medications. Its flagship application, Medsmart, collects data on medication usage, providing pharmaceutical companies with real-time intelligence about patient sentiment and behavior. The company offers various solutions, including a real-world persona data service, digital focus groups, and custom data solutions tailored to specific needs within the pharmaceutical sector. Founded in 2013 and rebranded in 2015, Talking Medicines aims to enhance regulatory compliance and enable marketing strategies through insights that measure patient confidence and identify growth opportunities for pharmaceutical brands.
Biotangents Ltd., founded in 2015 and based in Glasgow, United Kingdom, specializes in designing and building biological pathways for the production of valuable natural materials. The company utilizes its proprietary Leapfrog Assembly platform to create complex genetic constructs from various DNA components. Among its innovations is the development of terpenoid biosynthesis strains and the Short Sequence Randomisation technology for DNA randomisation. Biotangents has also conceptualized Moduleic Sensing, a modular cell-free nucleic acid detection technology, which led to the creation of a diagnostic test for identifying infectious diseases in livestock. This veterinary diagnostic device employs isothermal amplification technology, enabling precise detection without significant technical demands and allowing for quick adaptation to new targets. The solutions provided by Biotangents aim to mitigate the impact of infectious diseases in livestock, thereby enhancing the efficiency of animal protein production.
It is our mission to be a world leader in liquid biopsy and artificial intelligence for early detection of cancers and other diseases to improve survival and quality of life. Dxcover are an award-winning team, dedicated to developing liquid biopsies for early detection of cancer and other diseases. A University of Strathclyde spinout in 2019 under the name ClinSpec Diagnostics, and rebranded as Dxcover Limited in 2021. To date, Dxcover have secured £5.1m of funding, and have successfully completed two ground-breaking clinical studies on detection of brain cancer and are currently developing our platform for the detection of commonly occurring cancers.
Adaptix Limited designs and manufactures 3D radiology imaging equipment for X-ray imaging applications. It offers a technology for producing a miniaturized flat panel X-ray source that can be integrated into a manufacturers existing product line. The company’s solutions are used in bedside chest imaging, extremity imaging, dental imaging, and breast imaging. Adaptix Limited was formerly known as Radius Diagnostics Ltd and changed its name to Adaptix Limited in February 2015. The company was founded in 2009 and is based in Oxford, United Kingdom.
Calcivis Limited is a dental biologic and device manufacturing company based in Edinburgh, United Kingdom, focused on addressing tooth decay and enhancing preventive dentistry. Established in 2012, the company has developed a unique imaging system that provides live visualization of active tooth demineralization. This system incorporates CALCIVIS photoprotein, which emits light in response to free calcium ions released from demineralizing tooth surfaces. The imaging device captures this reaction, allowing dental professionals to assess and diagnose caries and other demineralization conditions effectively. By enabling early detection of active decay, the technology supports a preventive approach to dentistry, aiming to treat patients before cavities necessitate more invasive procedures. Calcivis was co-invented with contributions from the University of Dundee and LUX Innovate, and it operates a virtual development model in collaboration with various Scottish contract research and manufacturing organizations.
Biotangents Ltd., founded in 2015 and based in Glasgow, United Kingdom, specializes in designing and building biological pathways for the production of valuable natural materials. The company utilizes its proprietary Leapfrog Assembly platform to create complex genetic constructs from various DNA components. Among its innovations is the development of terpenoid biosynthesis strains and the Short Sequence Randomisation technology for DNA randomisation. Biotangents has also conceptualized Moduleic Sensing, a modular cell-free nucleic acid detection technology, which led to the creation of a diagnostic test for identifying infectious diseases in livestock. This veterinary diagnostic device employs isothermal amplification technology, enabling precise detection without significant technical demands and allowing for quick adaptation to new targets. The solutions provided by Biotangents aim to mitigate the impact of infectious diseases in livestock, thereby enhancing the efficiency of animal protein production.
Bio-Images Drug Delivery Ltd, located in Glasgow, United Kingdom, specializes in drug formulation and delivery systems. The company offers comprehensive services that include troubleshooting, formulation development, and both in vitro and in vivo testing. A key feature of their offerings is the patented OralogiK technology, which allows for precise control of drug release. This technology has been validated in clinical studies and enables the oral administration of single, multi-dose, or combination drugs at specific intervals ranging from one to twelve hours after ingestion. The benefits of this system include targeted night-time dosing, multi-phased drug delivery, and the ability to direct drugs to specific areas within the digestive system. Additionally, Bio-Images Drug Delivery employs gamma scintigraphy to assess the in vivo behavior of formulations, providing crucial data on disintegration times, gastric emptying, and gastrointestinal transit. The company's clinical division supports the entire clinical trial process, from protocol development to regulatory submissions and the production of compliant study reports.
Calcivis Limited is a dental biologic and device manufacturing company based in Edinburgh, United Kingdom, focused on addressing tooth decay and enhancing preventive dentistry. Established in 2012, the company has developed a unique imaging system that provides live visualization of active tooth demineralization. This system incorporates CALCIVIS photoprotein, which emits light in response to free calcium ions released from demineralizing tooth surfaces. The imaging device captures this reaction, allowing dental professionals to assess and diagnose caries and other demineralization conditions effectively. By enabling early detection of active decay, the technology supports a preventive approach to dentistry, aiming to treat patients before cavities necessitate more invasive procedures. Calcivis was co-invented with contributions from the University of Dundee and LUX Innovate, and it operates a virtual development model in collaboration with various Scottish contract research and manufacturing organizations.
Adaptix Limited designs and manufactures 3D radiology imaging equipment for X-ray imaging applications. It offers a technology for producing a miniaturized flat panel X-ray source that can be integrated into a manufacturers existing product line. The company’s solutions are used in bedside chest imaging, extremity imaging, dental imaging, and breast imaging. Adaptix Limited was formerly known as Radius Diagnostics Ltd and changed its name to Adaptix Limited in February 2015. The company was founded in 2009 and is based in Oxford, United Kingdom.
Metix Limited manufactures patient monitoring devices. The company was founded in 2013 and is based in Glasgow, United Kingdom.
Aurum Biosciences Ltd develops pharmaceuticals. The company’s products and technology include Perfluorocarbon which carry oxygen to organs and tissues; Magnetic Resonance Imaging which is a medical imaging technique that does not use ionising radiation and Proprietary image analysis software which provides accurate analyses of images of the stroke patient’s brain. Aurum Biosciences Ltd was founded in 2010 and is headquartered in Glasgow, United Kingdom.
Caldan Therapeutics Ltd is a biotechnology company that originated as a spinout from the University of Glasgow and the University of Southern Denmark. The company focuses on the development of novel therapeutics that target free fatty acid receptors, which play a significant role in the pathophysiology of metabolic diseases, particularly Type 2 Diabetes (T2D). Through a collaboration between Professor Graeme Milligan and Professor Trond Ulven, Caldan Therapeutics aims to address various aspects of T2D, including insulin secretion, insulin sensitivity, and islet cell protection. In addition to T2D, there is potential for the company's therapeutics to be applied in treating other conditions such as non-alcoholic steatohepatitis and inflammatory diseases.
Calcivis Limited is a dental biologic and device manufacturing company based in Edinburgh, United Kingdom, focused on addressing tooth decay and enhancing preventive dentistry. Established in 2012, the company has developed a unique imaging system that provides live visualization of active tooth demineralization. This system incorporates CALCIVIS photoprotein, which emits light in response to free calcium ions released from demineralizing tooth surfaces. The imaging device captures this reaction, allowing dental professionals to assess and diagnose caries and other demineralization conditions effectively. By enabling early detection of active decay, the technology supports a preventive approach to dentistry, aiming to treat patients before cavities necessitate more invasive procedures. Calcivis was co-invented with contributions from the University of Dundee and LUX Innovate, and it operates a virtual development model in collaboration with various Scottish contract research and manufacturing organizations.
i2Eye Diagnostics Limited, based in Edinburgh, United Kingdom, specializes in developing innovative ophthalmic medical devices that enhance the diagnosis and management of eye and optic nerve disorders. The company's primary product, Saccadic Vector Optokinetic Perimetry (SVOP), measures instinctive responses to light and movement, allowing for accurate visual field testing in pediatric and neuro-ophthalmology contexts. This technology is particularly beneficial for testing children and elderly patients who were previously challenging to assess. i2Eye Diagnostics is a spin-out from the University of Edinburgh and the Edinburgh BioQuarter, and it aims to provide a more accessible and effective approach to visual field analysis by incorporating advanced 3D eye tracking capabilities, which enables patients to move freely during tests without the need for response buttons. Founded in 2010, the company is committed to addressing critical clinical needs in the field of ophthalmology.
Clyde Biosciences Ltd. specializes in developmental drug testing solutions, focusing on cardiac cell analysis to provide insights into drug mechanisms and toxicity. The company has developed cellOPTIQ, an optical action potential assay that helps clients assess the cardiotoxicity risk of new and existing drugs by evaluating their effects on human cells. Additionally, Clyde Biosciences offers XTENDSR, which allows for direct measurements of drug-induced changes in cardiac sarcoplasmic reticulum function. By delivering human-relevant cardiomyocyte functional data, the company aids pharmaceutical and biotechnology firms in mitigating risks during drug development. Founded in 2012 and based in Glasgow, United Kingdom, Clyde Biosciences serves clients both domestically and internationally.
Relitect Limited engages in developing a technology for the detection of binding events, which can be used for the analysis of proteins, small molecules, and nucleic acids for clinical diagnostics and life sciences industries. The company was incorporated in 2014 and is based in Motherwell, United Kingdom.
DestiNA Genomics Ltd. is a molecular diagnostic company based in Edinburgh, United Kingdom, specializing in the detection of nucleic acids and single nucleotide polymorphisms (SNPs). Founded in 2010 as a spin-out from the University of Edinburgh, the company has developed a unique, chemical-based system that is distinct from traditional enzymatic methods. DestiNA offers a range of reagents and probes for the detection of nucleic acids and mutations, as well as assay sets for drug profiling and development. Its technology is particularly effective for direct detection of micro-RNAs and is being integrated into various detection platforms, including colorimetric, fluorescent, and electrochemical systems. DestiNA Genomics has also established a subsidiary in Spain, DestiNA Genomica SL, to exploit its technologies in collaboration with local partners. The Spanish subsidiary has received funding from the Technological Fund of Invest in Spain to support its research and development initiatives.
Bedi OralCare Limited, based in Edinburgh, United Kingdom, specializes in manufacturing dental products tailored for young children, individuals with disabilities, and dementia sufferers. Established in 2013, the company aims to enhance oral health accessibility for all. Its flagship product, Dental Shield, assists health professionals in examining patients by facilitating mouth opening for routine dental procedures. Another significant offering, the Bedi Tray, allows for dental impressions in preschool children without the need for restraint, promoting a more comfortable experience. The company is committed to improving the quality of life and overall well-being of its patients through its innovative dental care solutions.
Edinburgh Molecular Imaging Limited is a biotechnology company based in Edinburgh, United Kingdom, founded in 2014. The company specializes in optical molecular imaging technology that facilitates image-guided therapy for the detection, diagnosis, and monitoring of diseases. It focuses on the discovery and development of small molecules and peptides that can be conjugated with fluorescent dyes, allowing for real-time disease detection during interventional procedures, such as surgery. Edinburgh Molecular Imaging has raised over £15 million in non-dilutive funding from organizations like the Wellcome Trust, EPSRC, and MRC to advance its innovative SMART Agents, which enhance molecular imaging capabilities. The team behind the company comprises experienced scientists and clinicians with extensive expertise in medicinal chemistry, biochemistry, cell biology, and clinical development, positioning the company to contribute significantly to the field of medical imaging.
Bedi OralCare Limited, based in Edinburgh, United Kingdom, specializes in manufacturing dental products tailored for young children, individuals with disabilities, and dementia sufferers. Established in 2013, the company aims to enhance oral health accessibility for all. Its flagship product, Dental Shield, assists health professionals in examining patients by facilitating mouth opening for routine dental procedures. Another significant offering, the Bedi Tray, allows for dental impressions in preschool children without the need for restraint, promoting a more comfortable experience. The company is committed to improving the quality of life and overall well-being of its patients through its innovative dental care solutions.
Dysis Medical Ltd. is a medical device company based in Edinburgh, United Kingdom, specializing in the design, development, manufacture, and marketing of imaging systems for the non-invasive detection of cancerous and pre-cancerous lesions. The company's flagship product, the DYSIS Colposcope, utilizes patented optical and software techniques to scan the cervix, measure the aceto-whitening reaction, and present findings in an intuitive color-coded map. This technology aids medical practitioners in the early detection, diagnosis, and monitoring of cervical neoplasia, as well as in identifying biopsy sites. In addition to the colposcope, Dysis Medical offers various accessories, including disposable and reusable specula, diathermy loops, and coagulation balls, along with software for data management and image analysis. Founded in 2002 and previously known as FORTH Photonics Limited until its rebranding in 2011, Dysis Medical also operates sales offices in Tampa, Florida, and Athens, Greece.
Blackford Analysis Ltd. specializes in software solutions that enhance the comparison of medical images, thereby improving efficiency and productivity in healthcare settings. The company's key offerings include the Blackford Workflow Server, which integrates seamlessly into hospital IT systems to facilitate image pre-processing, and the Blackford Smart Localizer, designed for easy comparison of multiple imaging studies within the Philips IntelliSpace PACS interface. Furthermore, Blackford Custom Solutions provides libraries that support the Workflow Server, while the company also develops tailored image processing capabilities for various clients, including radiologists and healthcare enterprises. Founded in 2010 as a spin-out from the University of Edinburgh, Blackford Analysis has established partnerships with leading imaging system providers and has expanded its presence with sales offices in the UK and the USA. Through its innovative products, the company aims to save clinicians time and enhance communication across healthcare enterprises.
Blackford Analysis Ltd. specializes in software solutions that enhance the comparison of medical images, thereby improving efficiency and productivity in healthcare settings. The company's key offerings include the Blackford Workflow Server, which integrates seamlessly into hospital IT systems to facilitate image pre-processing, and the Blackford Smart Localizer, designed for easy comparison of multiple imaging studies within the Philips IntelliSpace PACS interface. Furthermore, Blackford Custom Solutions provides libraries that support the Workflow Server, while the company also develops tailored image processing capabilities for various clients, including radiologists and healthcare enterprises. Founded in 2010 as a spin-out from the University of Edinburgh, Blackford Analysis has established partnerships with leading imaging system providers and has expanded its presence with sales offices in the UK and the USA. Through its innovative products, the company aims to save clinicians time and enhance communication across healthcare enterprises.
Lab901
Venture Round in 2009
Lab901 Limited engages in the development and production of automated gel electrophories in the United Kingdom. It offers ScreenTape P200 variant, which allows scientists in expressing and purifying recombinant proteins and monoclonal antibodies to carry out SDS-PAGE and analysis; ScreenTape R6K that is developed for reproducible RNA characterisation and quality control; and ScreenTape D800, which separates DNA fragments.
Big DNA Ltd was set up in 2007 by Dr John March, as a spin out company from the Moredun Research Institute at Edinburgh University, to further develop and commercialise new vaccination technologies. Based at Roslin BioCentre, the company currently employs 7 people.
Lab901
Venture Round in 2008
Lab901 Limited engages in the development and production of automated gel electrophories in the United Kingdom. It offers ScreenTape P200 variant, which allows scientists in expressing and purifying recombinant proteins and monoclonal antibodies to carry out SDS-PAGE and analysis; ScreenTape R6K that is developed for reproducible RNA characterisation and quality control; and ScreenTape D800, which separates DNA fragments.
CXR Biosciences is advancing and commercializing innovative approaches to transform the drug development and chemical safety assessment process. As well as introducing new technology platforms to the marketplace, CXR also helps customers to take their candidate compounds through development efficiently, or to resolve problems that have been encountered, through the provision of customized solutions. The company has business relationships with over sixty customers and collaborators, including pharmaceutical companies, chemical companies, biotechnology companies, leading universities and research institutions.
Big DNA Ltd was set up in 2007 by Dr John March, as a spin out company from the Moredun Research Institute at Edinburgh University, to further develop and commercialise new vaccination technologies. Based at Roslin BioCentre, the company currently employs 7 people.
DC Biosciences Ltd specializes in providing proteomics services and molecular biology solutions to pharmaceutical and biotech companies, facilitating the development of drugs. The company offers a comprehensive technology portfolio, focusing on quantitative proteomics to support preclinical activities in drug discovery. Its services include biomarker discovery and validation, as well as drug re-profiling and repositioning. Key products offered by DC Biosciences include stable isotope labeling with amino acids in cell culture (SILAC) reagents, such as SILAC cell culture media and dialysed sera for SILAC applications, along with click chemistry reagents. Established in 2006 and originally known as Dundee Cell Products Ltd, the company rebranded to DC Biosciences Ltd in 2016 and is headquartered in Dundee, United Kingdom.
Lab901
Venture Round in 2005
Lab901 Limited engages in the development and production of automated gel electrophories in the United Kingdom. It offers ScreenTape P200 variant, which allows scientists in expressing and purifying recombinant proteins and monoclonal antibodies to carry out SDS-PAGE and analysis; ScreenTape R6K that is developed for reproducible RNA characterisation and quality control; and ScreenTape D800, which separates DNA fragments.